Indeed, several compounds, mainly monoclonal antibodies, are already available to inhibit the IL17 pathway (such as ixekizumab, brodalumab, or secukinumab), which are currently under evaluation or in use for treating auto-inflammatory diseases such as psoriasis or ankylosing spondyloarthritis [109–111]. The gene discussed is IL17A; the disease is psoriasis.